✦ LIBER ✦

860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ Scribed by O. Rixe; T.E. Hutson; P. Tomczak; M.D. Michaelson; R.M. Bukowski; S. Oudard; S. Negrier; S.T. Kim; I. Chen; R.A. Figlin; R.J. Motzer

Book ID: 119618177
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 328 KB
Volume: 6
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(07)60855-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III Study of Sunitinib Malate (SU1

Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma

✍ Kesava Reddy; Ronald M. Bukowski 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB

Randomized Phase III Trial of Temsirolim

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

✍ Hutson, T. E.; Escudier, B.; Esteban, E.; Bjarnason, G. A.; Lim, H. Y.; Pittman, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 258 KB

Phase I Trial of Sunitinib Malate plus I

Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma

✍ Robert J. Motzer; Gary Hudes; George Wilding; Lawrence H. Schwartz; Subramanian 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 130 KB

Randomized Phase II Trial of First-Line

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Coplen, D.E. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 69 KB

246 OVERALL SURVIVAL WITH SUNITINIB VERS

246 OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)

✍ C. Szczylik; S. Negrier; S. Oudard; R.A. Figlin; T.E. Hutson; P. Tomczak; M.D. M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 546 KB

3002 Final quality of life (QOL) results

3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

✍ D. Cella; M.D. Michaelson; A.G. Bushmakin; J.C. Cappelleri; C. Charbonneau; S.T. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB